Effects of treatment duration during concomitant chemoradiation therapy for cervical cancer

International Journal of Radiation Oncology Biology Physics

Volumn 86, Issue 3, 2013, Pages 562-568

  Shaverdian, Narek ^a   Gondi, Vinai ^a,b   Sklenar, Kathryn L ^a   Dunn, Emily F ^a   Petereit, Daniel G ^c   Straub, Margaret R ^a   Bradley, Kristin A ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b CENTRAL DUPAGE HOSPITAL   (United States)

^c RAPID CITY REGIONAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMORADIOTHERAPY; CHEMOTHERAPY; DISEASE CONTROL; DISEASES; HAZARDS; MULTIVARIANT ANALYSIS; PATIENT MONITORING; RADIATION EFFECTS; RADIOTHERAPY;

CONCOMITANT CHEMORADIATION; COX PROPORTIONAL HAZARDS MODELS; DISEASE-FREE SURVIVAL; EXTERNAL BEAM RADIATION THERAPY; KAPLAN-MEIER ANALYSIS; METHODS AND MATERIALS; MULTI VARIATE ANALYSIS; OVERALL SURVIVAL RATES;

PATIENT TREATMENT;

CISPLATIN; FLUOROURACIL; HYDROXYUREA; ANTINEOPLASTIC AGENT;

ADENOSQUAMOUS CARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ADULT; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; UTERINE CERVIX CANCER; AGE; ANALYSIS OF VARIANCE; CHEMORADIOTHERAPY; MORTALITY; PATHOLOGY; TIME; TUMOR RECURRENCE; UTERINE CERVIX TUMOR;

AGE FACTORS; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

MLCS; MLOWN;

EID: 84880575159     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.01.037     Document Type: Article

References (20)

1. Fyles A, Keane TJ, Barton M, et al. The effect of treatment in local control of cervix cancer. Radiother Oncol 1992;25:273-279.
2. Keane TJ, Fyles A, O'Sullivan B, et al. The effect of treatment on local control of squamous cell carcinoma of the tonsil and carcinoma of the cervix. Semin Radiat Oncol 1992;2:26-28.
3. Perez CA, Grigsby PW, Castro-Vita H, et al. Carcinoma of the uterine cervix. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1995;32:1275-1288.
4. Petereit DG, Skarai JN, Chappell R, et al. The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys 1995;32:1301-1307.
5. Chen SW, Liang JL, Yang SN, et al. The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy. Radiother Oncol 2003;67:69-76.
6. Huang ZH, Mayrn NA, Gao M, et al. Onset time of tumor repopulation for cervical cancer: First evidence from clinical data. Int J Radiat Oncol Biol Phys 2012;84:478-484.
7. Barton MB, Keane TJ, Gadalla T, et al. The effect of treatment time and treatment interruption on tumor control following radical radiotherapy of laryngeal cancer. Radiother Oncol 1992;23:137-143.
8. Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 1992;23:457-467.
9. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48:7-16.
10. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomized controlled trial. Lancet 2003;362:933-940.
11. Wendt TG, Grabenbauer GG, Rödel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomizedmulticenter study. JClinOncol 1998;16:1318-1324.
12. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Eng J Med 2010; 363:24-35.
13. Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004;22:872-880.
14. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Eng J Med 1999;340: 1154-1161.
15. Gondi V, Bentzen SM, Sklenar KL, et al. Severe late toxicities following concomitant chemoradiotherapy compared to radiotherapy alone in cervical cancer: An inter-eraanalysis. Int J Radiat Oncol Biol Phys 2012;84:973-982.
16. Stitt JA, Fowler JF, Thomadsen BR, et al. High dose rate intracavitary brachytherapy for carcinoma of the cervix: The Madison system: I. Clinical and radiobiological considerations. Int J Radiat Oncol Biol Phys 1992;24:335-348.
17. Thomadsen BR, Shahabi S, Stitt JA, et al. High dose rate intracavitary brachytherapy for carcinoma of the cervix: The Madison system: II. Procedural and physical considerations. Int J Radiat Oncol Biol Phys 1992;24:349-357.
18. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27:131-146.
19. Song S, Rudra S, Haselle MD, et al. The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy. Cancer 2013;119:325-331.
20. Pearcey R, Brundage M, Drouin P, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 2002;20:966-972.